Essex Investment Management Co. LLC purchased a new stake in Cascadian Therapeutics Inc (NASDAQ:CASC) during the fourth quarter, Holdings Channel reports. The fund purchased 153,180 shares of the biopharmaceutical company’s stock, valued at approximately $567,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CASC. Dimensional Fund Advisors LP increased its holdings in Cascadian Therapeutics by 423.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 511,899 shares of the biopharmaceutical company’s stock valued at $2,094,000 after acquiring an additional 414,019 shares during the last quarter. State Street Corp increased its holdings in Cascadian Therapeutics by 1,113.7% in the 2nd quarter. State Street Corp now owns 411,299 shares of the biopharmaceutical company’s stock valued at $1,527,000 after acquiring an additional 377,410 shares during the last quarter. Vanguard Group Inc. increased its holdings in Cascadian Therapeutics by 24.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,767,681 shares of the biopharmaceutical company’s stock valued at $6,567,000 after acquiring an additional 343,838 shares during the last quarter. Northern Trust Corp increased its holdings in Cascadian Therapeutics by 415.5% in the 2nd quarter. Northern Trust Corp now owns 382,469 shares of the biopharmaceutical company’s stock valued at $1,420,000 after acquiring an additional 308,270 shares during the last quarter. Finally, P.A.W. Capital Corp bought a new stake in Cascadian Therapeutics in the 3rd quarter valued at $982,000. Institutional investors own 80.35% of the company’s stock.

Shares of Cascadian Therapeutics Inc (CASC) opened at $9.97 on Friday. Cascadian Therapeutics Inc has a fifty-two week low of $3.18 and a fifty-two week high of $10.21. The firm has a market cap of $505.18, a PE ratio of -7.39 and a beta of 3.96.

Cascadian Therapeutics (NASDAQ:CASC) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01. During the same quarter in the prior year, the company earned ($0.09) earnings per share. equities analysts forecast that Cascadian Therapeutics Inc will post -1.27 EPS for the current year.

A number of analysts have recently weighed in on the stock. BidaskClub upgraded shares of Cascadian Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 31st. ValuEngine upgraded shares of Cascadian Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 31st. Zacks Investment Research upgraded shares of Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Monday, November 13th. Finally, Raymond James Financial downgraded shares of Cascadian Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 31st. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $5.63.

WARNING: “Essex Investment Management Co. LLC Purchases New Holdings in Cascadian Therapeutics Inc (CASC)” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/essex-investment-management-co-llc-purchases-new-holdings-in-cascadian-therapeutics-inc-casc/1855152.html.

Cascadian Therapeutics Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

Want to see what other hedge funds are holding CASC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cascadian Therapeutics Inc (NASDAQ:CASC).

Institutional Ownership by Quarter for Cascadian Therapeutics (NASDAQ:CASC)

Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.